Supporting Information

Supplementary Table 1. PICOS Table: Systematic Literature Review Eligibility Criteria

Study Characteristic	Criteria
Population	Adults, ≥18 years old, with a prior diagnosis of non-neurogenic OAB
Interventions	Vibegron 75 mg, mirabegron 25/50 mg, darifenacin 7.5/15 mg, fesoterodine 4/8 mg, imidafenacin 0.2 mg, oxybutynin 10/15 mg ER, oxybutynin 10/15 mg IR, propiverine 20 mg, solifenacin 5/10 mg, tolterodine 4 mg IR, tolterodine 4 mg ER, trospium 40/60 mg, placebo (oral), combination therapy (any treatment combination excluding those with solifenacin 2.5/10 mg or combinations with 2 anticholinergics); nonpharmacologic treatments were excluded
Comparisons	At least 2 of the interventions or placebo (oral)
Outcomes	Efficacy outcomes: mean change from baseline in daily total urinary incontinence episodes, daily number of micturitions, and total volume voided per micturition; safety outcomes: treatment-emergent adverse events and specific adverse events including dry mouth, constipation, blurred vision, and tachycardia; withdrawals for any reason
Time	Duration of treatment period, 48–52 weeks
Setting	No restriction on geographic or clinical settings
Study design	Randomized controlled trials, including parallel-group, crossover, and cluster trials
Publication types	Journal articles and reports, conference posters, systematic literature reviews, meta-analyses, network meta-analyses
Language	English
Date of publication	No temporal limit

ER, extended release; IR, immediate release; OAB, overactive bladder; PICOS, Population, Intervention, Comparison, Outcomes, Study Design.